Apogee Therapeutics, Inc.

Historical 13F Holders

Symbol
APGE
CUSIP
03770N101
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 03770N101 since 12/18/2024, largest first.

Filer % of Class Filed
BlackRock, Inc. 13G/A 5.5% 7/16/2025
Event 6/30/2025
Under 5%, checked the "5 percent or less" box, or amended by a later filing (8)
RTW Investments, LP 13G/A
4.9% 2/17/2026
Event 12/31/2025
Driehaus Capital Management LLC 13G/A 4.7% 11/14/2025
Event 9/30/2025
FMR LLC 13G/A
4.0% 7/8/2026
Event 6/30/2026
T. Rowe Price Investment Management, Inc. 13G/A 1.3% 7/8/2026
Event 6/30/2026
Wellington Management Group LLP 13G/A
0.9% 7/8/2026
Event 6/30/2026
Fairmount Funds Management LLC 13D/A
0% 9/3/2026
Event 9/3/2026
Vanguard Group Inc 13G/A 0% 3/26/2026
Event 3/13/2026
Venrock Healthcare Capital Partners III, L.P. 13D/A
0% 9/8/2026
Event 9/3/2026

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q2 310 73.3 M $8.97 B
2026 Q1 243 79.1 M $6.64 B
2025 Q4 219 71.3 M $5.34 B
2025 Q3 185 60.7 M $2.41 B
2025 Q2 201 58.0 M $2.52 B
2025 Q1 183 61.5 M $2.30 B
2024 Q4 166 57.9 M $2.62 B
2024 Q3 149 56.1 M $3.29 B
2024 Q2 146 54.4 M $2.14 B
2024 Q1 147 53.2 M $3.54 B
2023 Q4 89 41.9 M $1.17 B
2023 Q3 75 40.1 M $849 M